The abstract is read at the publisher; the summary is JClub's.
Lipoprotein apheresis selectively removes apoB100-containing lipoproteins in children with homozygous familial hypercholesterolaemia, helping prevent new aortic and coronary lesions and major cardiovascular events.
- Why it matters: Despite new lipid-lowering drugs, severe lipid disorders like HoFH and high lipoprotein(a) still leave patients with residual cardiovascular risk, and LA’s role needs clearer positioning.
- What they did: The review traces plasmapheresis evolution from 1960s pediatric HoFH care to modern selective LA, and discusses its endothelial and microcirculation effects alongside emerging pharmacologic options.
- The result: LA is presented as a safe option for severe lipid disorders when LDL-cholesterol targets are not reached or lipoprotein(a) is elevated, while underdiagnosis, therapeutic inertia, and limited qualified centers remain barriers.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.